EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 399 filers reported holding EXELIXIS INC in Q3 2022. The put-call ratio across all filers is 0.65 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $5,689,494 | +17.4% | 253,204 | +24.0% | 0.07% | +1.4% |
Q1 2024 | $4,846,425 | +29.2% | 204,232 | +30.6% | 0.07% | +4.3% |
Q4 2023 | $3,751,916 | +15.8% | 156,395 | +5.5% | 0.07% | +4.5% |
Q3 2023 | $3,240,508 | +49.0% | 148,307 | +30.3% | 0.07% | +42.6% |
Q2 2023 | $2,175,502 | -11.0% | 113,841 | -9.6% | 0.05% | -20.3% |
Q1 2023 | $2,443,583 | -37.9% | 125,893 | -48.7% | 0.06% | -46.8% |
Q4 2022 | $3,937,098 | +189.1% | 245,455 | +182.5% | 0.11% | +170.7% |
Q3 2022 | $1,362,000 | -16.3% | 86,876 | +11.2% | 0.04% | -21.2% |
Q2 2022 | $1,627,000 | +186.4% | 78,129 | +212.0% | 0.05% | +188.9% |
Q1 2022 | $568,000 | +46.4% | 25,045 | +18.0% | 0.02% | +38.5% |
Q4 2021 | $388,000 | -40.0% | 21,222 | -30.7% | 0.01% | -50.0% |
Q3 2021 | $647,000 | -21.4% | 30,629 | -9.0% | 0.03% | 0.0% |
Q3 2020 | $823,000 | -6.6% | 33,666 | -9.3% | 0.03% | 0.0% |
Q2 2020 | $881,000 | +4.4% | 37,102 | -24.3% | 0.03% | +13.0% |
Q1 2020 | $844,000 | -54.8% | 49,007 | -53.7% | 0.02% | -32.4% |
Q4 2019 | $1,866,000 | -81.5% | 105,901 | -81.4% | 0.03% | -80.9% |
Q3 2019 | $10,060,000 | +171.3% | 568,830 | +227.8% | 0.18% | +201.7% |
Q2 2019 | $3,708,000 | -1.5% | 173,522 | +9.7% | 0.06% | +7.3% |
Q1 2019 | $3,763,000 | +53.0% | 158,124 | +26.4% | 0.06% | +44.7% |
Q4 2018 | $2,460,000 | +163.9% | 125,062 | +137.7% | 0.04% | +192.3% |
Q3 2018 | $932,000 | -69.5% | 52,608 | -63.0% | 0.01% | -70.5% |
Q2 2018 | $3,057,000 | -42.6% | 142,058 | -40.9% | 0.04% | -40.5% |
Q1 2018 | $5,323,000 | -59.7% | 240,326 | -44.7% | 0.07% | -61.5% |
Q4 2017 | $13,203,000 | -37.2% | 434,309 | -49.9% | 0.19% | -37.7% |
Q3 2017 | $21,010,000 | -20.5% | 867,089 | -19.2% | 0.31% | -17.0% |
Q2 2017 | $26,427,000 | +31.9% | 1,072,961 | +16.1% | 0.37% | +46.1% |
Q1 2017 | $20,029,000 | +218.0% | 924,289 | +118.8% | 0.25% | +213.6% |
Q4 2016 | $6,299,000 | +278.8% | 422,461 | +224.8% | 0.08% | +268.2% |
Q3 2016 | $1,663,000 | +878.2% | 130,059 | +498.4% | 0.02% | +1000.0% |
Q2 2016 | $170,000 | – | 21,735 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |